Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)

Next Previous
X
Search
Trial Profile

An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carotuximab (Primary) ; Sorafenib
  • Indications Liver cancer; Liver cirrhosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TRACON Pharmaceuticals

    • Most Recent Events

    • 04 Oct 2019 Status changed from active, no longer recruiting to completed.
    • 12 Apr 2019 According to a TRACON Pharmaceuticals media release, based on a review of TAPPAS trial data, the Independent Data Monitoring Committee (IDMC) recommended to terminate TAPPAS trial. The company also decided to terminate further enrollment in company sponsored trials of TRC105 in oncology.
    • 12 Apr 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top